In the latter, Lyn up-regulation and activation are associated with expression of Bcl-2, which is often silenced in BCR-ABL-positive CML cells, which in turn confers imatinib resistance (100). Here, LYN is linked to chronic myelogenous leukemia, BCR-ABL1 positive.